These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25134047)

  • 41. Effects of time-based administration of abstinence reinforcement targeting opiate and cocaine use.
    Toegel F; Holtyn AF; Subramaniam S; Silverman K
    J Appl Behav Anal; 2020 Jul; 53(3):1726-1741. PubMed ID: 32249414
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
    Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
    Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement.
    Carroll KM; Ball SA; Nich C; O'Connor PG; Eagan DA; Frankforter TL; Triffleman EG; Shi J; Rounsaville BJ
    Arch Gen Psychiatry; 2001 Aug; 58(8):755-61. PubMed ID: 11483141
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.
    Sullivan M; Bisaga A; Pavlicova M; Choi CJ; Mishlen K; Carpenter KM; Levin FR; Dakwar E; Mariani JJ; Nunes EV
    Am J Psychiatry; 2017 May; 174(5):459-467. PubMed ID: 28068780
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors associated with using opiates while under extended-release naltrexone blockade: A descriptive pilot study.
    Jarvis BP; DeFulio A; Long L; Holtyn AF; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    J Subst Abuse Treat; 2018 Feb; 85():56-60. PubMed ID: 28161142
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
    Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
    Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology.
    Mooney LJ; Nielsen S; Saxon A; Hillhouse M; Thomas C; Hasson A; Stablein D; McCormack J; Lindblad R; Ling W
    Contemp Clin Trials; 2013 Mar; 34(2):196-204. PubMed ID: 23159524
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone.
    Sullivan MA; Bisaga A; Glass A; Mishlen K; Pavlicova M; Carpenter KM; Mariani JJ; Levin FR; Nunes EV
    Drug Alcohol Depend; 2015 Feb; 147():122-9. PubMed ID: 25555621
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [An interim analysis of the results of treatment program implementation with the use of injectable extended-release naltrexone for opioid addicted patients].
    Agibalova TV; Nedobylskiy OV; Poplevchenkov KN; Sirotko II; Shcherban AV; Tsarev SA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):32-34. PubMed ID: 28745668
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of oral and implantable naltrexone in the management of the opioid impaired physician.
    Hulse GK; O'Neil G; Hatton M; Paech MJ
    Anaesth Intensive Care; 2003 Apr; 31(2):196-201. PubMed ID: 12712786
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concurrent substance use and outcome in combined behavioral and naltrexone therapy for opiate dependence.
    Church SH; Rothenberg JL; Sullivan MA; Bornstein G; Nunes EV
    Am J Drug Alcohol Abuse; 2001 Aug; 27(3):441-52. PubMed ID: 11506261
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acceptability and efficacy of naltrexone for criminal justice-involved individuals with opioid use disorder: a systematic review and meta-analysis.
    Bahji A; Carlone D; Altomare J
    Addiction; 2020 Aug; 115(8):1413-1425. PubMed ID: 31863669
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence.
    Pettinati HM; Kampman KM; Lynch KG; Dundon WD; Mahoney EM; Wierzbicki MR; O'Brien CP
    Am J Addict; 2014; 23(6):591-7. PubMed ID: 25251201
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advances in opioid antagonist treatment for opioid addiction.
    Ling W; Mooney L; Wu LT
    Psychiatr Clin North Am; 2012 Jun; 35(2):297-308. PubMed ID: 22640757
    [No Abstract]   [Full Text] [Related]  

  • 55. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.
    Coviello DM; Cornish JW; Lynch KG; Boney TY; Clark CA; Lee JD; Friedmann PD; Nunes EV; Kinlock TW; Gordon MS; Schwartz RP; Nuwayser ES; O'Brien CP
    Subst Abus; 2012; 33(1):48-59. PubMed ID: 22263713
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
    Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
    Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.
    Williams AR; Barbieri V; Mishlen K; Levin FR; Nunes EV; Mariani JJ; Bisaga A
    Am J Addict; 2017 Jun; 26(4):319-325. PubMed ID: 28328148
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings.
    Sinha R; Kimmerling A; Doebrick C; Kosten TR
    Psychopharmacology (Berl); 2007 Mar; 190(4):569-74. PubMed ID: 17136399
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Financial incentives promote engagement in employment services for unemployed adults in treatment for opioid use disorder.
    Holtyn AF; Toegel F; Subramaniam S; Arellano M; Leoutsakos JM; Fingerhood M; Silverman K
    Drug Alcohol Depend; 2020 Jul; 212():107982. PubMed ID: 32370931
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
    Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG
    J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.